Table 1.
Patient characteristics.
| Melphalan (n=19) | Mitomycin-C (n=29) | p-value | |
|---|---|---|---|
| Gender | 0.048 | ||
| Male, n (%) | 5 (26) | 16 (55) | |
| Female, n (%) | 14 (74) | 13 (45) | |
| Number of previous surgeries with curative intent | 0.99 | ||
| 0 (%) | 2 (10) | 4 (14) | |
| 1 (%) | 15 (80) | 21 (72) | |
| >1 (%) | 2 (10) | 4 (14) | |
| Median LN resected from previous surgery, (range) | 15 (0-43) | 14 (0-145) | 0.87 |
| LN metastases at the time of previous surgery, n (%) | 12 (71) | 18 (67) | 1 |
| Adjuvant chemotherapy after previous surgery, n (%) | 17 (90) | 25 (86) | 0.9 |
| Location of tumor origin | 0.88 | ||
| Right, n (%) | 6 (32) | 8 (28) | |
| Left, n (%) | 13 (68) | 21 (72) | |
| Peritoneal carcinomatosis occurrence | 0.63 | ||
| Synchronous, n (%) | 8 (42) | 11 (38) | |
| Metachronous, n (%) | 13 (58) | 18 (62) | |
|
| |||
| At the time of CRS/HIPEC | |||
|
| |||
| NACT (before HIPEC), n (%) | 1 (5) | 2 (7) | 1 |
| Mean age at the time of CRS/HIPEC, years (SD) | 52±11 | 51±9 | 0.73 |
| Median time from diagnosis to CRS/HIPEC, months (range) | 22 (0-82) | 16 (0-97) | 0.89 |
| Median preoperative PCI (range) | 17 (3-35) | 13 (3-39) | 0.86 |
| PCI≥20, (%) | 9 (47) | 13 (45) | 1 |
| Median LOS, minutes | 569 | 580 | 0.78 |
| Median LN resected from CRS/HIPEC, n (range) | 26 (6-119) | 17 (1-53) | 0.07 |
| Lymph nodes metastases, n (%) | 8 (42) | 12 (46)† | 0.73 |
| Median length of stay in hospital, days (range) | 11 (7-17) | 10 (5-59) | 0.89 |
| Histopathology | 0.98 | ||
| Well differentiated, n (%) | 2 (11) | 3 (10) | |
| Moderately differentiated, n (%) | 16 (84) | 17 (59) | |
| Poorly differentiated, n (%) | 1(5) | 8 (28) | |
| Not reported, n (%) | 0 (0) | 1 (3) | |
NACT: neoadjuvant chemotherapy; LOS: length of surgery; †calculated in 26 patients (not reported in 3 patients).